U.S. FDA Concluded Inspection of Lupin’s Novel Laboratories

March 31, 2022, 2:51 PM UTC

The inspection closed with 13 observations, the company said in a filing on Thursday.

  • The observations won’t disrupt supplies or impact existing revenues from operations of this facility
  • Novel Labs is Lupin’s facility in Somerset, U.S.

To contact the reporter on this story:
Suvashree Ghosh in Mumbai at sghosh186@bloomberg.net

To contact the editors responsible for this story:
Stefania Bianchi at sbianchi10@bloomberg.net

Anto Antony

© 2022 Bloomberg L.P. All rights reserved. Used with permission.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.